Human Genome Sciences announces clearance of investigational a new anticancer drug application for the treatment of B-cell tumor
- Phase 1 clinical study to begin in multiple myeloma patients -
16-May-2002 -
ROCKVILLE, Maryland, May 14, 2002 – Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to begin clinical trials of LymphoRad™131 (LymphoRad). Human Genome Sciences’ initial Phase 1 ...
blood cancer
chronic lymphocytic leukemia
clinical trials
+7